07:22 AM EST, 11/19/2025 (MT Newswires) -- Merck ( MRK ) said Wednesday that the European Commission has approved a subcutaneous injectable version of its cancer drug Keytruda for all 33 approved indications in Europe.

The subcutaneous version of the drug can be administered in one minute every three weeks or in two minutes every six weeks, said Marjorie Green, head of oncology at Merck Research Laboratories.

The approval was based on a clinical trial, which showed that Keytruda SC showed comparable results to the intravenous version of the drug.